Zynerba Pharmaceuticals I... (ZYNE)
NASDAQ: ZYNE
· Real-Time Price · USD
1.30
0.03 (2.36%)
At close: Oct 10, 2023, 10:00 PM
Zynerba Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -38.79M | -36.82M | -35.25M | -35.4M | -37.12M | -37.79M | -36.77M | -38.12M | -37.14M | -49.15M |
Interest Income | 1.54M | 1.2M | 846.86K | 444.02K | 197.21K | 111.46K | 21.05K | 21.54K | 27.28K | 47.94K |
Pretax Income | -37.58M | -36.66M | -35.04M | -35.83M | -37.74M | -37.84M | -37.31M | -38.11M | -36.58M | -46.96M |
Net Income | -37.01M | -36.77M | -35.5M | -36.7M | -38.43M | -37.84M | -37.31M | -38.11M | -36.58M | -46.96M |
Selling & General & Admin | 14.03M | 13.79M | 14.15M | 14.75M | 15.16M | 15.83M | 15.35M | 16.1M | 15.66M | 15.77M |
Research & Development | 24.75M | 23.03M | 21.1M | 20.65M | 21.96M | 21.96M | 21.42M | 22.02M | 21.48M | 33.38M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 38.79M | 36.82M | 35.25M | 35.4M | 37.12M | 37.79M | 36.77M | 38.12M | 37.14M | 49.15M |
Interest Expense | 251.85K | 343.55K | 343.55K | 343.55K | 91.69K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.79M | 36.82M | 35.25M | 35.4M | 37.12M | 37.79M | 36.77M | 38.12M | 37.14M | 49.15M |
Income Tax Expense | -573.07K | 111.17K | 468.5K | 784.24K | 600.97K | -83.27K | -6.45K | 76.82K | 76.82K | 76.82K |
Shares Outstanding (Basic) | 50.15M | 48.43M | 45.13M | 43.75M | 41.41M | 40.3M | 40.23M | 40.09M | 40.07M | 40.07M |
Shares Outstanding (Diluted) | 50.15M | 48.43M | 45.13M | 43.75M | 41.41M | 40.3M | 40.23M | 40.09M | 40.07M | 40.07M |
EPS (Basic) | -0.78 | -0.82 | -0.83 | -0.88 | -0.94 | -0.94 | -0.93 | -1.04 | -1.09 | -1.62 |
EPS (Diluted) | -0.78 | -0.82 | -0.83 | -0.88 | -0.94 | -0.94 | -0.93 | -1.04 | -1.09 | -1.62 |
EBITDA | -38.47M | -36.5M | -34.93M | -34.93M | -37.14M | -37.81M | -36.79M | -38.27M | -37.29M | -49.3M |
EBIT | -27.98M | -26.6M | -35.5M | -35.93M | -37.71M | -37.79M | -36.77M | -27.93M | -26.96M | -38.96M |
Depreciation & Amortization | 430.96K | 1.2M | 1.11M | 1.44M | 1.01M | 246.38K | 247.14K | 245.03K | 240.92K | 227.27K |